Results 41 to 50 of about 15,419 (219)

PKD1 gene rs7185040 polymorphism and progression of chronic kidney disease in patients with ADPKD [PDF]

Journal of Nephropathology
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a commonly encountered genetic condition contributing to chronic renal failure in both pediatric and adult populations. Roughly 89% of individuals with ADPKD exhibit mutation in either
Aiswarya Kosaraju, Sandhya Suresh, Ramprasad Elumalai, Gnanasambandan Ramanathan   +3 more
doaj   +1 more source

A Comparison of Urine Dilution Ability between Adult Dominant Polycystic Kidney Disease, Other Chronic Kidney Diseases, and Healthy Control Subjects: A Case-Control Study

International Journal of Nephrology, 2020
The final dilution of urine is regulated via aquaporin-2 water channels in the distal part of the nephron. It is unclear whether urine dilution ability in autosomal dominant polycystic kidney disease patients (ADPKD patients) differs from other patients ...
M. H. Malmberg, F. H. Mose, E. B. Pedersen, J. N. Bech   +3 more
doaj   +1 more source

Biological Efficacy and Safety of Niacinamide in Patients With ADPKD

Kidney International Reports, 2020
Introduction Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst enlargement, leading to kidney failure. Sirtuin-1 is upregulated in ADPKD and accelerates disease progression by deacetylating p53.
M. El Ters, Xia Zhou, R. Lepping, Pengcheng Lu, Rainer T. Karcher, J. Mahnken, W. Brooks, Franz T. Winklhofer, Xiaogang Li, A. Yu   +9 more
semanticscholar   +1 more source

MicroRNA501‐5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells

Journal of Cellular Physiology, 2018
Lucia De Stephanis, Peter C Harris, Paolo Pinton   +2 more
exaly   +2 more sources

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Drug, Healthcare and Patient Safety, 2022
Rupesh Raina,1– 3 Ahmad Houry,1,3 Pratik Rath,1 Guneive Mangat,1 Davinder Pandher,1,4 Muhammad Islam,3 Ala’a Grace Khattab,3 Joseph K Kalout,1 Sumedha Bagga5 1Akron Nephrology Associates/Cleveland Clinic Akron General Medical Center, Akron, OH, USA ...
Raina R, Houry A, Rath P, Mangat G, Pandher D, Islam M, Khattab AG, Kalout JK, Bagga S   +8 more
doaj  

Targeting Cyst Initiation in ADPKD [PDF]

Journal of the American Society of Nephrology, 2009
With approximately 12.5 million people worldwide affected by autosomal dominant polycystic kidney disease (ADPKD), one hopes we are now at the beginning of multiple therapeutic breakthroughs. ADPKD is a hereditary disorder caused by a genetic defect in either polycystin-1 ( PKD1 ; PC1) or polycystin-2 ( PKD2 ; PC2) that leads to progressive kidney cyst
Stephanie J, Leuenroth, Craig M, Crews
openaire   +2 more sources

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Journal of the American Society of Nephrology, 2018
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to
F. Chebib, R. Perrone, A. Chapman, N. Dahl, P. Harris, M. Mrug, R. Mustafa, A. Rastogi, T. Watnick, A. Yu, V. Torres   +10 more
semanticscholar   +1 more source

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

American Society of Nephrology. Clinical Journal, 2020
BACKGROUND AND OBJECTIVES Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity.
M. Bargagli, N. Dhayat, M. Anderegg, Mariam Semmo, U. Huynh-Do, B. Vogt, P. M. Ferraro, D. Fuster   +7 more
semanticscholar   +1 more source

Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD

JBMR Plus, 2021
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of chronic kidney disease (CKD) and leads to a specific type of bone disease.
Renata C Pereira, Berenice Y Gitomer, Michel Chonchol, Peter C Harris, Kathleen J Noche, Isidro B Salusky, Lauren V Albrecht   +6 more
doaj   +1 more source

A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells

Scientific Reports, 2020
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited monogenic disorders, characterized by a progressive decline in kidney function due in part to the formation of fluid-filled cysts.
Rosita R. Asawa, Carina Danchik, A. Zakharov, Yuchi Chen, T. Voss, A. Jadhav, D. Wallace, J. Trott, R. Weiss, A. Simeonov, Natalia J Martinez   +10 more
semanticscholar   +1 more source